Analysts Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $7.00

Shares of Precigen, Inc. (NASDAQ:PGEN) have earned an average rating of “Moderate Buy” from the five analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $7.00.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Precigen in a research report on Friday, November 15th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in PGEN. Iridian Asset Management LLC CT grew its stake in Precigen by 82.5% in the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock worth $3,576,000 after purchasing an additional 1,706,815 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Precigen by 4.8% in the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after purchasing an additional 149,829 shares during the period. State Street Corp increased its stake in Precigen by 1.0% during the third quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock valued at $2,720,000 after purchasing an additional 29,253 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Precigen by 11.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock worth $1,158,000 after purchasing an additional 127,467 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Precigen by 12.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock worth $1,869,000 after buying an additional 130,500 shares during the last quarter. 33.51% of the stock is owned by institutional investors and hedge funds.

Precigen Price Performance

PGEN opened at $0.73 on Thursday. Precigen has a 12 month low of $0.65 and a 12 month high of $1.93. The stock has a market capitalization of $212.71 million, a P/E ratio of -1.32 and a beta of 1.71. The business has a 50 day simple moving average of $0.83 and a 200-day simple moving average of $1.11.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.